Thursday, 28 May 2026
  
Login

Australia's most trusted
source of pharma news

Thursday, 28 May 2026
News

Lilly muscles into vaccine market

Posted 28 May 2026 AM

Lilly is bursting into the vaccine space, spending up to $5.29 billion to acquire three early-stage biotechs with a range of technologies across a range of diseases.

While much of the growth of the largest pharma in the world is expected to come from obesity drugs, Lilly has traditionally had a broad portfolio, and this move is seen by analysts as a push to diversify future revenue streams.

To see the whole article, please login

Popular

Exec exits with pointed sign-off
Drug pulled after viability review
Oncology dethroned as No 1
Partnership boosts clinical trials
Latest Jobs
Pharma in Focus  Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home